Marine-derived anticancer agents in clinical trials (Q30969641)

27 June 2017

Marine-derived anticancer agents in clinical trials (English)

1 reference

27 June 2017

Gilberto Schwartsmann

1

1 reference

27 June 2017

Adriana Brondani Da Rocha

2

1 reference

27 June 2017

Jane Mattei

3

1 reference

27 June 2017

RafaelMartins Lopes

4

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Expert Opinion on Investigational Drugs

27 June 2017

1 reference

27 June 2017

12

1 reference

27 June 2017

8

1 reference

27 June 2017

1367-1383

1 reference

Natural products in anticancer therapy.

27 June 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Discovery and development of antineoplastic agents from natural sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Paclitaxel (Taxol): a success story with valuable lessons for natural product drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Neuraxial infusion in patients with chronic intractable cancer and noncancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

In vitro hematotoxicity of Aplidine on human bone marrow and cord blood progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Actin-binding marine macrolides: total synthesis and biological importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Pharmacological characterization of the pseudopterosins: novel anti-inflammatory natural products isolated from the Caribbean soft coral, Pseudopterogorgia elisabethae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Marine organisms as a source of new anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Drugs from the seas - current status and microbiological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Natural products as probes of cell biology: 20 years of didemnin research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Structure--activity relationships of the didemnins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Interactions of antimitotic peptides and depsipeptides with tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Mitochondrial cytochrome c release is caspase-dependent and does not involve mitochondrial permeability transition in didemnin B-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

A phase I clinical trial of didemnin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a Southwest Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Progress in the discovery of biosynthetic anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Effect of pharmacologic manipulation of protein kinase C by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte-macrophage progenitors to recombinant GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Squalamine: an aminosterol antibiotic from the shark

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

The pseudopterosins: anti-inflammatory and analgesic natural products from the sea whip Pseudopterogorgia elisabethae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

An evaluation of intrathecal ziconotide for the treatment of chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Calcium channel blockers and pain therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Role of calcium channels in the spinal transmission of nociceptive information from the mesentery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Blood pressure changes after intrathecal co-administration of calcium channel blockers with morphine or clonidine at the spinal level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Synthesis and comparison of the antiinflammatory activity of manoalide and cacospongionolide B analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Defense of Ascidians and Their Conspicuous Larvae: Adult vs. Larval Chemical Defenses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Isolation and structure of bryostatin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1367

Halichondrins - antitumor polyether macrolides from a marine sponge

21 January 2018

1 reference

20 August 2023

https://opencitations.net/index/coci/api/v1/citations/10.1351/PAC198658050701

Safracins, new antitumor antibiotics. II. Physicochemical properties and chemical structures

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.36.1284

Identifiers

DOI

10.1517/13543784.12.8.1367

1 reference

27 June 2017

1 reference